SCHEMBL4910869

SCHEMBL4910869

CC(CCc1ccc(Cl)c(Cl)c1)N(C)CCCN

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 14/20 0.51
GRIN2D O15399 1/20 0.51
GRIN3B O60391 1/20 0.51
GRIN1 Q05586 1/20 0.51
GRIN2A Q12879 1/20 0.51
GRIN2B Q13224 1/20 0.51
GRIN2C Q14957 1/20 0.51
GRIN3A Q8TCU5 1/20 0.51
PNMT P11086 2/20 0.50
TAAR1 Q96RJ0 1/20 0.50
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
TMEM97 Q5BJF2 4/20 0.44
KDM4E B2RXH2 1/20 0.42
KCNH2 Q12809 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4719154 0.80 SIGMAR1 (0.50) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL4760458 0.78 SIGMAR1 (0.59) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
Bromide SCHEMBL4761361 0.75 PYGL (0.49) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
Bromide SCHEMBL4761598 0.75 PYGL (0.48) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL9160104 0.74 SIGMAR1 (0.67) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL4668444 0.74 SLC6A4 (0.40) SIGMAR1PNMTTAAR1ALDH1A1KCNH2
SCHEMBL2538061 0.73 SIGMAR1 (0.58) SIGMAR1PNMTTAAR1MEN1ALDH1A1
SCHEMBL4037320 0.73 PNMT (0.76) SIGMAR1PNMTTAAR1MEN1ALDH1A1
SCHEMBL4636336 0.72 CYP1A2 (0.52) SIGMAR1PNMTTAAR1MEN1ALDH1A1
SCHEMBL4910377 0.72 PNMT (0.58) SIGMAR1PNMTTAAR1MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293745-A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands SANOFI-AVENTIS (FR) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293745-A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands CCR3, CCR1, CCR4 SIGMAR1 636/4885GRIN2D 3040/4885GRIN3B 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.